Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

Abstract

The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.

• Authors: G W Kaatz, S M Seo, J R Aeschlimann, H H Houlihan, R C Mercier, M J Rybak
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 42 Issue 4 Pg. 981-3 (Apr 1998) ISSN: 0066-4804 [Print] United States
• PMID: 9559828 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Glycopeptides
• Lipoglycopeptides
• Vancomycin
• oritavancin

Topics

• Animals
• Anti-Bacterial Agents (blood, therapeutic use)
• Colony Count, Microbial
• Endocarditis, Bacterial (drug therapy, microbiology)
• Glycopeptides
• Kidney (microbiology)
• Lipoglycopeptides
• Male
• Methicillin Resistance
• Rabbits
• Spleen (microbiology)
• Staphylococcal Infections (drug therapy, microbiology)
• Vancomycin (blood, therapeutic use)